Last update 21 Nov 2024
RC-148
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism PD-1 modulators(Programmed cell death protein 1 modulators), VEGF modulators(Vascular endothelial growth factor modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 160581189
Related
4
Clinical Trials associated with RC-148A Randomized, Open-label, Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With RC148 Versus Albumin-bound Paclitaxone Alone or in Combination With Toripalimab in Subjects With HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Safety, Tolerability, Pharmacokinetics, and Efficacy of RC148 in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors: an Open-Label, Multicenter, Phase I Trial
评价RC148注射液单药及联合方案治疗局部晚期不可切除或转移性恶性实体肿瘤患者的疗效和安全性的多中心Ⅰ/Ⅱ期临床研究
[Translation] A multicenter phase I/II clinical study to evaluate the efficacy and safety of RC148 injection alone and in combination with other drugs in the treatment of patients with locally advanced unresectable or metastatic malignant solid tumors
100 Clinical Results associated with RC-148
Login to view more data
100 Translational Medicine associated with RC-148
Login to view more data
100 Patents (Medical) associated with RC-148
Login to view more data
100 Deals associated with RC-148
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HR-negative/HER2-low Breast Carcinoma | Phase 2 | CN | 01 Nov 2024 | |
| Malignant Solid Neoplasm | Phase 2 | CN | 07 Sep 2023 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | CN | 14 Sep 2023 | |
| CLDN18.2 Positive Advanced Malignant Solid Neoplasm | IND Approval | CN | 25 Jul 2024 | |
| HER2-Low Breast Carcinoma | IND Approval | CN | 23 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free